Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Nov 14;5(2):164–178. doi: 10.1158/1940-6207.CAPR-11-0391

Figure 2.

Figure 2

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. In each case, Kaplan-Meier analysis was restricted to participants who had taken ≥ 2 years’ intervention and the analysis was adjusted for gender (hazard ratio 0.41 (95% confidence interval, 0.19–0·86), P = 0·02). Each point on the plot shows the estimated cumulative incidence by years of follow-up, together with the corresponding 95% confidence interval.